<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Opioid use disorder: Overview of treatment during pregnancy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Opioid use disorder: Overview of treatment during pregnancy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Opioid use disorder: Overview of treatment during pregnancy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Neil S Seligman, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Emily Rosenthal, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vincenzo Berghella, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lynn L Simpson, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrew J Saxon, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vanessa A Barss, MD, FACOG
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Friedman, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 11, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Opioid use disorder (OUD) may involve heroin, diverted or misused prescription opioids, or other morphine-like drugs (eg,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         ). OUD during pregnancy is associated with substantial maternal, fetal, and neonatal risks. These risks are related to repeated opioid exposure (eg, risk of overdose) as well as factors associated with opioid use (eg, smoking, poor nutrition, needle sharing, unstable lifestyle).
        </p>
        <p>
         Medication for OUD (MOUD) is recommended for pregnant patients and should be accompanied by close supportive clinical follow-up. The goal is to prevent maternal, obstetric, and neonatal complications associated with OUD, provide an entry into recovery, facilitate prenatal care, and help patients avoid the myriad risks from the unstable lifestyle associated with substance use (eg, drug-related criminal activity, housing instability, intimate partner violence, infectious disease) [
         <a href="#rid1">
          1-3
         </a>
         ]. While
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         has been the standard choice for MOUD during pregnancy since the 1970s,
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         is increasingly used because neonatal withdrawal (also known as neonatal abstinence syndrome) appears to be less severe when the pregnant patient is treated with buprenorphine as opposed to methadone [
         <a href="#rid4">
          4
         </a>
         ]. Continuous use of either treatment during pregnancy appears to reduce the odds of preterm birth compared with discontinuing opioid agonist treatment [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         This topic will provide an overview of the management of OUD in pregnant and postpartum patients. Administration of
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         and
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         pharmacotherapy, as well as fetal/neonatal effects, are discussed separately (see
         <a class="medical medical_review" href="/z/d/html/87238.html" rel="external">
          "Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy"
         </a>
         ). General issues related to prevalence, screening, complications, and care of the pregnant patient with OUD are also discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4799.html" rel="external">
          "Substance use during pregnancy: Screening and prenatal care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/128152.html" rel="external">
          "Substance use during pregnancy: Overview of selected drugs", section on 'Opioids'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          MOUD OR MEDICALLY ASSISTED WITHDRAWAL?
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment with either
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         or
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         plus psychosocial treatment is the preferred approach to treatment of OUD during pregnancy given the many benefits of medication for OUD (MOUD)  (
         <a class="graphic graphic_table graphicRef55718" href="/z/d/graphic/55718.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid6">
          6-13
         </a>
         ]. Either methadone or buprenorphine is provided throughout pregnancy and the postpartum period to prevent withdrawal symptoms and reduce or eliminate cravings. The medication may be continued for years beyond the postpartum period; the duration of therapy in nonpregnant individuals is reviewed separately (see
         <a class="medical medical_review" href="/z/d/html/108803.html" rel="external">
          "Opioid use disorder: Treatment overview"
         </a>
         ). Psychosocial interventions, such as addiction counseling, peer support groups, and/or structured, multimodal care, are provided concurrently to support the patient in recovery and reduce the risk of relapse. (See
         <a class="medical medical_review" href="/z/d/html/99647.html" rel="external">
          "Opioid use disorder: Psychosocial management"
         </a>
         .)
        </p>
        <p>
         Medically assisted opioid withdrawal followed by psychosocial treatment is an alternative, but it is not recommended because a high proportion of patients return to using opioids [
         <a href="#rid14">
          14-21
         </a>
         ]. In medically assisted opioid withdrawal,
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         or
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         is provided to prevent withdrawal symptoms and reduce or eliminate cravings, but the dose is then gradually reduced to the lowest dose that prevents withdrawal symptoms and then reduced further until the medication can be discontinued. Following withdrawal, psychosocial interventions should be provided to support the patient and reduce the risk of relapse. The American Society of Addiction Medicine does not consider medically assisted withdrawal to be a standalone treatment for OUD. (See
         <a class="local">
          'Medically assisted opioid withdrawal'
         </a>
         below.)
        </p>
        <p>
         These two approaches have never been compared in a randomized trial involving pregnant patients. The process of medically assisted withdrawal is no longer thought to be associated with adverse fetal outcomes [
         <a href="#rid22">
          22,23
         </a>
         ]. However, in nonpregnant patients treated for OUD, pharmacotherapy has had greater efficacy in reducing recidivism and maintaining abstinence compared with medically assisted withdrawal followed by nonpharmacologic psychosocial treatment [
         <a href="#rid24">
          24,25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H671768726">
         <span class="h1">
          CANDIDATES FOR MOUD
         </span>
         <span class="headingEndMark">
          —
         </span>
         All pregnant patients with OUD, as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)  (
         <a class="graphic graphic_table graphicRef50295" href="/z/d/graphic/50295.html" rel="external">
          table 2
         </a>
         ), are candidates for medication for OUD (MOUD). The duration of OUD is not a criterion for eligibility if continuation of, or return to, illicit opioid use is likely during pregnancy. (See
         <a class="medical medical_review" href="/z/d/html/7807.html" rel="external">
          "Substance use disorders: Clinical assessment", section on 'Assessment/Diagnosis'
         </a>
         .)
        </p>
        <p>
         Candidates for treatment should be referred to a clinician with training and familiarity with MOUD and/or to an OUD treatment program. Barriers to treatment include lack of health insurance or resources to self-pay, incarceration, transportation and childcare needs, guilt about the effect of drugs on the fetus, and fear of legal consequences, including loss of custody of children.
        </p>
        <p>
         Treatment programs that are oriented to abstinence only and do not utilize or understand MOUD should be avoided.
        </p>
        <p class="headingAnchor" id="H2083252449">
         <span class="h1">
          METHADONE OR BUPRENORPHINE?
         </span>
         <span class="headingEndMark">
          —
         </span>
         Programs in the United States that treat OUD during pregnancy use either
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         or
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         for first-line therapy. Buprenorphine is available as a monoproduct or in combination with
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         , an opioid antagonist [
         <a href="#rid26">
          26,27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/87238.html" rel="external">
          "Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy", section on 'Use of combined buprenorphine and naloxone formulation'
         </a>
         .)
        </p>
        <p>
         The overall pros and cons of the two medications for pharmacotherapy are summarized in the table  (
         <a class="graphic graphic_table graphicRef87713" href="/z/d/graphic/87713.html" rel="external">
          table 3
         </a>
         ). The Substance Abuse and Mental Health Services Administration (SAMHSA) has also published a table of decision considerations when selecting
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         or
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         for pregnant patients  (
         <a class="graphic graphic_table graphicRef118512" href="/z/d/graphic/118512.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
         The American College of Obstetricians and Gynecologists (ACOG) and other major medical organizations [
         <a href="#rid10">
          10,11,28
         </a>
         ] have concluded that the available evidence supports the use of either
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         or
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         as a potential first-line medication for pregnant patients with OUD who are new to treatment [
         <a href="#rid2">
          2,29
         </a>
         ]. As a result of the ACOG opinion and increasing data suggesting decreased severity of neonatal withdrawal with buprenorphine use, use of buprenorphine in pregnancy has increased [
         <a href="#rid30">
          30,31
         </a>
         ]. However, the improvement in neonatal outcome may be related to differences in baseline characteristics between patients who are offered methadone versus buprenorphine treatment.
        </p>
        <p class="headingAnchor" id="H947115195">
         <span class="h2">
          Our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         We consider the following factors when counseling patients about their options; the choice of medication (
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         versus
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         ) is a shared decision.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Program availability
         </strong>
         – A list of local opioid treatment programs can be found
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindtreatment.samhsa.gov%2F&amp;token=14M7rzgwJS8UQt93I1lwE%2FvKUj7Y4V6ZQQY1%2BJpfgOzTY4sqcCpA%2B%2FjmOGUXU2HI&amp;TOPIC_ID=4790" target="_blank">
          online
         </a>
         . In many areas of the country, need for treatment greatly exceeds capacity. Regulations for dispensing
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         are different from and more restrictive than those for dispensing
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/87238.html" rel="external">
          "Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy", section on 'Provider'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/87238.html" rel="external">
          "Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy", section on 'Provider'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Availability of comprehensive treatment
         </strong>
         –
         <strong>
         </strong>
         Successful treatment with medication for OUD (MOUD) depends upon a comprehensive, multidisciplinary, coordinated approach to care [
         <a href="#rid32">
          32,33
         </a>
         ]. Most pregnant patients will benefit from opioid treatment programs that offer all of the following at a single site: MOUD; psychiatry and social worker services; individual and group counseling; case management; and prenatal care, including health and parenting counseling. Opioid treatment programs that specialize in care of pregnant individuals generally provide all of these services on-site, in contrast to an office-based setting where a clinician prescribes
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         and the only requirement is a "capacity to refer" the patient for counseling [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient preference
         </strong>
         –
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          Methadone
         </a>
         generally has to be dispensed to the patient on a daily basis by a registered opioid treatment program.
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          Buprenorphine
         </a>
         can also be provided by an opioid treatment program but can also be prescribed in an office-based setting. Patients can receive a prescription for up to 30 days of buprenorphine, fill the prescription at a pharmacy, and take the medication as prescribed on their own.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The office setting allows more privacy and convenience since patients do not come in daily for treatment. For some patients, geographic and economic limitations (eg, childcare, transportation costs) are barriers to attending an opioid treatment program on a daily basis. Although office settings are convenient, less frequent clinical contact can also be disadvantageous and may make an office-based setting less suitable for some individuals.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maternal and perinatal outcome
         </strong>
         –
         <strong>
         </strong>
         Both
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         and
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         are effective MOUD, and neither appears to be teratogenic [
         <a href="#rid35">
          35
         </a>
         ]. For the pregnant person, buprenorphine may pose a lower risk of overdose mortality than methadone because of the "ceiling effect" [
         <a href="#rid36">
          36,37
         </a>
         ], but does not appear to reduce the risk of severe maternal complications compared with methadone [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/87238.html" rel="external">
          "Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy", section on 'Pharmacology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For the newborn, in utero exposure to
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         rather than
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         has been associated with a lower risk of preterm birth, higher birth weight, larger head circumference, neonatal abstinence syndrome (NAS; discussed below), and possibly less severe NAS [
         <a href="#rid35">
          35,39-41
         </a>
         ]. Severity of NAS, although important to consider, is not necessarily the most important factor in choosing MOUD during pregnancy because NAS, when properly identified and managed, has not been associated with long-term harm. (See
         <a class="medical medical_review" href="/z/d/html/5016.html" rel="external">
          "Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neonatal abstinence syndrome (NAS)
         </strong>
         – The landmark Maternal Opioid Treatment: Human Experimental Research (MOTHER) trial is the largest randomized trial comparing pregnancy outcome among pregnant patients with OUD randomly assigned to treatment with
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         or
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         at eight international sites [
         <a href="#rid39">
          39
         </a>
         ]. Compared with methadone, buprenorphine resulted in significantly [
         <a href="#rid42">
          42
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lower doses of
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         for treatment of NAS (mean total 1.1 versus 10.4 mg)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Shorter duration of treatment for NAS (4.1 versus 9.9 days)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Shorter neonatal hospital stay (10.0 versus 17.5 days)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, there were several limitations to this trial, such as its small size (175 pregnancies) and a statistically nonsignificant but markedly higher attrition rate from the
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         treatment arm than from the
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         arm (33 versus 18 percent), which may have been due to the buprenorphine dosing protocol. The usual maximum dose of sublingual buprenorphine (32 mg daily) may not have been sufficient to prevent symptoms of withdrawal in some pregnant patients (usually those requiring &gt;140 mg methadone daily).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A large cohort study of a Medicaid dataset also reported benefits associated with use of
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         . This study included over 13,000 pregnant persons exposed to buprenorphine and over 6000 exposed to
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         who had a live birth [
         <a href="#rid38">
          38
         </a>
         ]. Compared with methadone, buprenorphine was associated with:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A nearly 30 percent reduction in NAS (52 versus 69 percent; aRR 0.73, 95% CI 0.71-0.75) in those exposed in the 30 days before delivery
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A 40 percent reduction in preterm birth
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A 25 percent reduction in small for gestational age newborn
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A 45 percent reduction in low birth weight
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Similar risks for severe maternal complications (defined as potentially life-threatening conditions caused or aggravated by pregnancy [eg, organ failure, myocardial infarction, coma, delirium, cerebrovascular disorder, pulmonary edema or embolism, sepsis, shock, disseminated intravascular coagulation])
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Key strengths of this study include the large sample size and adjustment for known confounders, including the use of a propensity-score analysis for early, late, and within 30 days before delivery exposure windows to balance all measured covariates among the exposure groups. Sensitivity analyses to address possible misclassification bias and unmeasured confounding resulted in similar findings.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maternal treatment retention
         </strong>
         – Ultimately, the best treatment option is the one that maximizes retention in treatment and prenatal care while minimizing recidivism. An analysis of data from three randomized trials [
         <a href="#rid39">
          39,43,44
         </a>
         ] found no difference between
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         and
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         for maternal retention in treatment [
         <a href="#rid45">
          45
         </a>
         ]. However, each of the three trials also reported lower rates of opioid use during pregnancy among participants assigned to methadone. Thus, although use of buprenorphine may lower neonatal resource utilization (eg, days in neonatal intensive care) and cost [
         <a href="#rid39">
          39
         </a>
         ], it may not achieve the primary objective of effective MOUD for all patients. Of note, in males and nonpregnant females, methadone maintenance is associated with greater treatment retention than buprenorphine [
         <a href="#rid25">
          25,46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">
          "Opioid use disorder: Pharmacologic management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/108803.html" rel="external">
          "Opioid use disorder: Treatment overview"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although a meta-analysis that included these randomized trials and additional cohort studies noted that pregnant patients treated with
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         were less likely to use opioids near delivery than those treated with
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         (RR 0.44, 95% CI 0.28-0.70), it is likely that differences in patient characteristics between the two treatment groups accounted for this finding [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H870031340">
         <span class="h2">
          Other pharmacotherapy
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">
          Naltrexone
         </a>
         – Naltrexone (an opioid antagonist) is available in oral, injectable, and implantable forms (implant not approved in the United States). There is a paucity of high-quality prospective data with regard to its use in pregnancy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Data from a small, retrospective cohort study including 68 naltrexone-exposed neonates reported outcomes comparable to using
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         or
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         in pregnancy, except that urogenital anomalies appeared to be more frequent in naltrexone-exposed fetuses. The authors did not state if these anomalies occurred with first-trimester exposure [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the largest study, which prospectively compared 121 patients with
         <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">
          naltrexone
         </a>
         medication-assisted treatment with 109 patients with
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         or
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         medication-assisted treatment, naltrexone was well tolerated by both mother and fetus, and no neonates who were exposed to the drug in utero up to delivery experienced symptoms of neonatal abstinence syndrome [
         <a href="#rid48">
          48
         </a>
         ]. Blood levels were similar in cord and maternal blood and were not detected if naltrexone was discontinued &gt;60 hours before delivery. There were no congenital anomalies reported in the 23 infants with first-trimester exposure.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a retrospective cohort study comparing six pregnant patients on
         <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">
          naltrexone
         </a>
         with 13 matched controls on
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         , the rate of neonatal opioid withdrawal syndrome (NOWS) was less in the naltrexone group (0 versus 92 percent in the buprenorphine group), which resulted in reductions in neonatal treatment for NOWS and length of stay [
         <a href="#rid49">
          49
         </a>
         ]. There were no significant differences in congenital anomalies, birthweight, head circumference, or Apgar scores.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If
         <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">
          naltrexone
         </a>
         is maintained until delivery, opioids are not likely to be effective for intrapartum and postpartum pain control. Expert panelists of the Substance Abuse and Mental Health Services Administration disagreed regarding continuing naltrexone use during pregnancy [
         <a href="#rid50">
          50
         </a>
         ]. A joint workshop of the Society for Maternal-Fetal Medicine, ACOG, and American Society of Addiction Medicine concluded that data are insufficient to support the initiation of naltrexone therapy in pregnancy, but it may be continued for those patients who already are taking this medication after discussion of the risks of discontinuing naltrexone (eg, risk of relapse) and the limitations of data of its use in pregnancy [
         <a href="#rid12">
          12
         </a>
         ]. One (ER) of the three authors of this topic uses naltrexone in their clinical practice in select cases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kratom
         </strong>
         – Kratom, an herb with opioid- and stimulant-like properties, should
         <strong>
          not
         </strong>
         be used in patients withdrawing from opioids. Pregnant patients have used kratom for self-treatment for OUD [
         <a href="#rid51">
          51
         </a>
         ]. There is little published evidence of efficacy and increasing numbers of reports of lethal overdose and other adverse effects. A systematic review of six case reports of Kratom exposure in pregnancy found neonatal withdrawal and maternal withdrawal requiring treatment in five of six of the cases [
         <a href="#rid52">
          52
         </a>
         ]. Maternal outcomes were not reported in one of the cases [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          Buprenorphine
         </a>
         has been used in pregnancy to treat kratom use disorder [
         <a href="#rid51">
          51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7808.html" rel="external">
          "Opioid withdrawal: Medically supervised withdrawal during treatment for opioid use disorder", section on 'Kratom'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          PRETREATMENT MATERNAL EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         A thorough medical, psychosocial, and physical assessment should be performed, given the prevalence of concomitant medical disorders, the socially and environmentally complex lives of individuals with OUD, and their frequent lack of consistent medical care [
         <a href="#rid53">
          53,54
         </a>
         ]. Care should be empathetic and nonjudgmental, with a focus on building a strong patient-provider relationship [
         <a href="#rid55">
          55,56
         </a>
         ]. This may reduce negative interactions and improve patient satisfaction.
        </p>
        <p class="headingAnchor" id="H1159649849">
         <span class="h2">
          Confidentiality
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are special considerations with regard to confidentiality when treating patients with OUD or other substance use disorders.
         <strong>
         </strong>
         For example, programs or providers in the United States are prevented from disclosing information identifying a patient as having a substance use disorder without written consent from the patient [
         <a href="#rid57">
          57
         </a>
         ]. Clinicians should be familiar with local laws and regulations.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          History
         </span>
         <span class="headingEndMark">
          —
         </span>
         A detailed and accurate medical and obstetric history can usually be obtained if the questions are asked in a direct and nonjudgmental way (see
         <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">
          "Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment", section on 'Assessment'
         </a>
         ). The following four areas are of particular concern in this population.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Social history
         </strong>
         – In one report, 83 percent of pregnant patients entering
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         treatment programs came from households in which the parents used substances, 67 percent had been victims of sexual assault, and 60 percent had been physically assaulted [
         <a href="#rid32">
          32
         </a>
         ]. Adverse childhood events such as physical, emotional, and sexual abuse or neglect are strongly associated with substance use disorder. One large retrospective cohort study found that people with a history of five or more adverse childhood events were 7 to 10 times more likely to report illicit drug use and addiction [
         <a href="#rid58">
          58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15294.html" rel="external">
          "Intimate partner violence: Diagnosis and screening"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15306.html" rel="external">
          "Intimate partner violence: Intervention and patient management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2765.html" rel="external">
          "Evaluation and management of adult and adolescent sexual assault victims in the emergency department"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Depression
         </strong>
         – We agree with the American College of Obstetricians and Gynecologists' recommendation for screening for depression and other behavioral health conditions [
         <a href="#rid2">
          2
         </a>
         ], as co-occurring mental health conditions are common (50 to 65 percent) [
         <a href="#rid59">
          59,60
         </a>
         ]. Among pregnant patients enrolled in a
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         treatment program, 30 percent had moderate-to-severe depression, and 40 percent reported postpartum depression [
         <a href="#rid61">
          61
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/83303.html" rel="external">
          "Prenatal care: Second and third trimesters", section on 'Mental health screening'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tobacco use
         </strong>
         – Approximately 80 to 90 percent of pregnant patients with OUD also smoke cigarettes [
         <a href="#rid14">
          14,62-65
         </a>
         ]. The combination of tobacco and
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         delays the onset of neonatal abstinence syndrome and increases the severity of neonatal withdrawal [
         <a href="#rid66">
          66-68
         </a>
         ]. In addition, tobacco use has multiple adverse effects on maternal health and pregnancy outcome. For all of these reasons, and others, smoking cessation is recommended. (See
         <a class="medical medical_review" href="/z/d/html/4803.html" rel="external">
          "Cigarette and tobacco products in pregnancy: Impact on pregnancy and the neonate"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/115306.html" rel="external">
          "Tobacco and nicotine use in pregnancy: Cessation strategies and treatment options"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Illicit substances or alcohol
         </strong>
         – It is common for patients who use opioids during pregnancy to use more than one illicit substance or misuse alcohol [
         <a href="#rid69">
          69
         </a>
         ]. Polysubstance use is associated with an increased risk of preterm birth. As an example, a retrospective cohort study including 258 neonates born to patients with OUD treated with
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         reported the rates of preterm birth among those using 0, 1, 2, or ≥3 substances (alcohol or illicit drugs) in addition to methadone were approximately 24, 26, 48, and 65 percent, respectively [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Polysubstance use can also affect medication for OUD (MOUD), depending on the substance and interaction. For example, barbiturates induce
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         metabolism, while benzodiazepines like
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         may act synergistically, causing excessive sedation [
         <a href="#rid71">
          71-74
         </a>
         ]. Chronic alcohol use may lower methadone levels through induction of hepatic enzymes, while acute consumption can accentuate methadone effects. (See
         <a class="medical medical_review" href="/z/d/html/4798.html" rel="external">
          "Alcohol intake and pregnancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Important aspects of the physical examination are listed in the table  (
         <a class="graphic graphic_table graphicRef55487" href="/z/d/graphic/55487.html" rel="external">
          table 5
         </a>
         ) and reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">
          "Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment", section on 'Physical examination'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Laboratory tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine prenatal laboratory tests are performed. (See
         <a class="medical medical_review" href="/z/d/html/446.html" rel="external">
          "Prenatal care: Initial assessment", section on 'Laboratory tests'
         </a>
         .)
        </p>
        <p>
         Laboratory tests of specific significance in this population include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urine toxicology screening to monitor for continued substance use. Toxicology screening is performed serially; the frequency during treatment is described separately. (See
         <a class="medical medical_review" href="/z/d/html/87238.html" rel="external">
          "Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy", section on 'Role of urine drug testing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Screening for tuberculosis. (See
         <a class="medical medical_review" href="/z/d/html/8014.html" rel="external">
          "Tuberculosis disease (active tuberculosis) in pregnancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Screening for sexually transmitted infections at the first prenatal visit and repeated in the third trimester in patients who remain at increased risk. (See
         <a class="medical medical_review" href="/z/d/html/83303.html" rel="external">
          "Prenatal care: Second and third trimesters", section on 'Screen for sexually transmitted infections'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         HIV counseling and testing using an opt-out approach (ie, testing will be done routinely unless a patient explicitly refuses). (See
         <a class="medical medical_review" href="/z/d/html/3753.html" rel="external">
          "HIV and women", section on 'HIV and pregnancy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hepatitis B and C and liver chemistry tests (eg, hepatitis B surface antigen, anti-hepatitis C virus antibodies, aspartate aminotransferase [AST], alanine aminotransferase [ALT]).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Hepatitis B vaccination is recommended for patients with negative serology. (See
         <a class="medical medical_review" href="/z/d/html/442.html" rel="external">
          "Immunizations during pregnancy", section on 'Hepatitis B'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chlamydia, gonorrhea, syphilis, and
         <em>
          Trichomonas vaginalis
         </em>
         (in settings where the prevalence is high). (See
         <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">
          "Screening for sexually transmitted infections"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         One or two ultrasound examinations before 22+0
         <sup>
         </sup>
         weeks of gestation are performed routinely during pregnancy because early ultrasound estimation
         <sup>
         </sup>
         is superior to pregnancy dating based on the last menstrual period or physical examination, and also provides information about fetal development. Females who have been using nonprescribed opioids frequently have irregular menses, so ultrasound is essential to establish gestational age. (See
         <a class="medical medical_review" href="/z/d/html/5388.html" rel="external">
          "Overview of ultrasound examination in obstetrics and gynecology", section on 'Obstetric sonography'
         </a>
         .)
        </p>
        <p>
         For patients who present for prenatal care late in pregnancy, ultrasound still provides useful information, but it is less accurate for estimating the date of delivery. (See
         <a class="medical medical_review" href="/z/d/html/5391.html" rel="external">
          "Prenatal assessment of gestational age, date of delivery, and fetal weight"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1618256565">
         <span class="h1">
          INDUCTION AND MAINTENANCE METHADONE AND BUPRENORPHINE DOSING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Issues related to administration of
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         and
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         in pregnant and postpartum patients, including dosing and side effects, are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/87238.html" rel="external">
          "Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H375898940">
         <span class="h1">
          PRENATAL CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Coordination of care between obstetric providers and the other providers (eg, addiction medicine, psychiatry, primary care, pediatrics, social service) is important. Routine aspects of prenatal care are discussed in detail separately. In general, a history of OUD per se, whether receiving medication for OUD (MOUD) or not, does not alter the frequency of prenatal care visits. (See
         <a class="medical medical_review" href="/z/d/html/446.html" rel="external">
          "Prenatal care: Initial assessment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83303.html" rel="external">
          "Prenatal care: Second and third trimesters"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112420.html" rel="external">
          "Prenatal care: Patient education, health promotion, and safety of commonly used drugs"
         </a>
         .)
        </p>
        <p>
         Obstetric providers should be aware of the reporting requirements related to OUD within their community/state/country [
         <a href="#rid75">
          75,76
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1590168272">
         <span class="h2">
          Antenatal fetal monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal method of fetal assessment during initial patient stabilization and initiation of pharmacotherapy ("induction") is unknown; no data are available to support any protocol. In our practice, we perform a daily nonstress test in pregnancies &gt;24 weeks of gestation admitted for inpatient stabilization during induction of pharmacotherapy. Abnormal results are managed according to standard obstetric protocols, with consideration of the effect of opioids on fetal biophysical parameters (discussed below) (see
         <a class="medical medical_review" href="/z/d/html/457.html" rel="external">
          "Overview of antepartum fetal assessment", section on 'Management of pregnancies with abnormal test results'
         </a>
         ). Hospital admission is not mandatory for patients beginning MOUD, though admission is not uncommon for coordination of care. Daily nonstress testing is not performed in patients who undergo induction on MOUD as outpatients.
        </p>
        <p>
         After the initial period of stabilization and initiation of MOUD, we believe continued antepartum fetal testing (nonstress test, biophysical profile [BPP]) does not improve pregnancy outcome in patients who consistently demonstrate good adherence by negative urine toxicology screens and have no standard indications for fetal surveillance. However, for patients with evidence of ongoing substance use or those who have other indications for fetal surveillance (eg, preeclampsia, fetal growth restriction), weekly or twice weekly testing during the third trimester is reasonable, as these pregnancies are probably at higher risk of abnormal fetal testing warranting intervention. (See
         <a class="medical medical_review" href="/z/d/html/457.html" rel="external">
          "Overview of antepartum fetal assessment", section on 'Indications for fetal assessment'
         </a>
         .)
        </p>
        <p>
         Opioids, like other central nervous system depressants, can affect the fetal heart rate, resulting in decreased variability and fewer accelerations [
         <a href="#rid77">
          77
         </a>
         ]. To reduce the chances of nonreactive nonstress test or a low BPP score related to opioids, we suggest delaying the test until at least four to six hours after MOUD is consumed, if possible. If daily fetal monitoring is performed, we suggest performing the test just before consuming the dose.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Effect of
         </strong>
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         <strong>
          on fetal biophysical parameters
         </strong>
         – Methadone use decreases fetal heart rate reactivity (higher frequency of nonreactive nonstress tests), increases time to achieve a reactive nonstress test [
         <a href="#rid78">
          78-81
         </a>
         ] and increases time to complete the BPP score [
         <a href="#rid79">
          79,82
         </a>
         ]. Reductions have been observed in [
         <a href="#rid83">
          83-85
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fetal baseline heart rate
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fetal heart rate variability
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Number of heart rate accelerations
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fetal breathing movements
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fetal movement
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a study of 16 pregnancies between 28 and 40 weeks in patients on
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         , scores for the modified BPP were the same before and after methadone dosing in 75 percent of the pregnancies, but it took on average 16 minutes longer to complete the modified BPP after methadone dosing (mean time 20 minutes) [
         <a href="#rid79">
          79
         </a>
         ]. Others have also reported minimal impact of the BPP score [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Effect of
         </strong>
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         <strong>
          on fetal biophysical parameters
         </strong>
         – In studies evaluating fetal neurobehavior during periods of peak and trough buprenorphine concentration, buprenorphine was associated with reductions in fetal heart rate, heart rate variability, and heart rate accelerations [
         <a href="#rid86">
          86,87
         </a>
         ]. However, these effects are less pronounced than those seen with
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         and may not significantly affect interpretation of tests of fetal well-being.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients treated with
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         tend to have greater fetal heart rate variability; more accelerations; better coupling between fetal movement and heart rate in early gestation (24 to 28 weeks); and longer, more frequent movements in later gestation (32 to 36 weeks) than those treated with
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         [
         <a href="#rid86">
          86
         </a>
         ]. The suppressive effects of buprenorphine are most notable in later gestation (&gt;32 weeks) and at higher doses (&gt;13 mg) [
         <a href="#rid87">
          87
         </a>
         ]. Compared with fetal testing postmethadone dosing, postbuprenorphine dosing nonstress tests are more likely to be reactive (adjusted odds ratio [OR] 0.13, 95% CI 0.04-0.48) and BPP scores are likely to be higher (8.7 versus 8.2; p&lt;0.02) [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1590168334">
         <span class="h2">
          Assessment for growth restriction
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no consistent effect of MOUD on fetal growth. Because several studies have demonstrated an association between OUD and low birth weight, particularly in untreated patients [
         <a href="#rid88">
          88
         </a>
         ], we and others perform ultrasound assessment of fetal growth in the third trimester, between 28 and 32 weeks [
         <a href="#rid89">
          89-91
         </a>
         ]. Impaired fetal growth is more likely to be a concern in those patients with ongoing substance use. Regardless, if there is a clinical suspicion of fetal growth restriction (eg, lagging fundal height), an ultrasound examination is indicated, and management is the same as for any pregnancy complicated by impaired fetal growth. (See
         <a class="medical medical_review" href="/z/d/html/6768.html" rel="external">
          "Fetal growth restriction: Evaluation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          LABOR AND DELIVERY
         </span>
        </p>
        <p class="headingAnchor" id="H2607138374">
         <span class="h2">
          Intrapartum methadone and buprenorphine dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The patient's usual oral
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         or
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         dose is continued intrapartum (during labor or before scheduled cesarean birth) to prevent withdrawal. (See
         <a class="medical medical_review" href="/z/d/html/87238.html" rel="external">
          "Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy", section on 'Intrapartum and postpartum methadone dosing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/87238.html" rel="external">
          "Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy", section on 'Intrapartum and postpartum buprenorphine dosing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h2">
          Labor and delivery management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial evaluation of any patient with OUD on the labor and delivery unit should include a medication history (including medication for OUD (MOUD) dose verification); inquiry about use of opioids, alcohol, and tobacco; urine toxicology; and testing for sexually transmitted infections (which may include rapid HIV testing), if not already performed in the third trimester. (See
         <a class="local">
          'Laboratory tests'
         </a>
         above.)
        </p>
        <p>
         Most patients on the labor unit have an intravenous (IV) line or IV access placed early in labor in case of an emergency (eg, hemorrhage, nonreassuring fetal tracing). This is particularly important in this population because peripheral access may be difficult due to sclerosed veins, scars, and cellulitis.
        </p>
        <p>
         Routine aspects of labor and delivery management are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/4445.html" rel="external">
          "Labor and delivery: Management of the normal first stage"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1089654595">
         <span class="h2">
          Analgesia and anesthesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neuraxial anesthesia is a common approach to pain management during labor and delivery in the general obstetric population and a good option for patients on MOUD [
         <a href="#rid12">
          12
         </a>
         ].
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          Buprenorphine
         </a>
         and
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         do not interfere with regional or local anesthetics. The goal of peripartum pain management is to provide adequate analgesia while avoiding both overmedication and withdrawal. The following are important principles to keep in mind:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Health care professionals concerned about drug-seeking behavior and overmedication may make the erroneous assumption that the daily maintenance dose of
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         or
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         alone provides analgesia. Although pharmacotherapy for OUD provides analgesia, long-term opioid exposure leads to tolerance (increasing amount of drug to achieve the same response) and opioid-induced hyperalgesia (increased sensitivity to pain) [
         <a href="#rid56">
          56,92
         </a>
         ]. Patients who report acute pain with objective findings are less likely to be exhibiting drug-seeking behavior.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is no evidence that exposure to opioid analgesics in the setting of acute pain increases rates of relapse in patients with OUD [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Efforts to achieve adequate pain control in patients with OUD should be similar to that in patients without such disorders, and include both pharmacologic (nonopioid and opioid) and nonpharmacologic approaches.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute intrapartum pain should not be treated with additional doses of
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         or
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher than usual opioid analgesic doses may be required because tight binding to the mu-opioid receptor blocks the analgesic effects of full opioid agonists; opioid cross-tolerance to anesthetics and other depressants occurs, a result of chronic receptor stimulation [
         <a href="#rid94">
          94
         </a>
         ]; and patients have increased pain sensitivity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although acceptable pain control can be achieved in clinical practice without clinically important central nervous system or respiratory depression, patients should be closely monitored because significant depression, though unlikely, is possible. Sedatives, opioids (including intrathecal), and general anesthetics should be administered cautiously since these drugs can potentiate the central nervous system depressant and analgesic effects of pharmacotherapy of OUD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the absence of neuraxial analgesia, opioids, such as
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         , can be used safely in early labor. For labor pain, we give 6 to 10 mg of morphine IV to patients dilated less than 6 cm. Alternatively, patient-controlled analgesia (PCA) can be used, but neonatal depression should be anticipated if IV or PCA opioids are used throughout labor.
         <a class="drug drug_general" data-topicid="9820" href="/z/d/drug information/9820.html" rel="external">
          Promethazine
         </a>
         25 mg IV is commonly given to laboring patients in conjunction with morphine. However, this combination in patients also taking
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         , or nonprescribed opioids can increase the potential for respiratory depression, so treatment with opioids alone or dose modification with close maternal monitoring is recommended.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Opioid antagonists or agonist-antagonists can precipitate acute withdrawal and should be avoided [
         <a href="#rid95">
          95,96
         </a>
         ]. Examples of these drugs are
         <a class="drug drug_general" data-topicid="9676" href="/z/d/drug information/9676.html" rel="external">
          nalbuphine
         </a>
         hydrochloride,
         <a class="drug drug_general" data-topicid="9753" href="/z/d/drug information/9753.html" rel="external">
          pentazocine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9179" href="/z/d/drug information/9179.html" rel="external">
          butorphanol
         </a>
         tartrate, and
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         . If any of these drugs are given inadvertently, withdrawal can be reversed with any full opioid agonist [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         (See
         <a class="medical medical_review" href="/z/d/html/130304.html" rel="external">
          "Obstetric anesthesia for patients with opioid use disorder or opioid tolerance"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1632892729">
         <span class="h1">
          POSTPARTUM CARE
         </span>
        </p>
        <p class="headingAnchor" id="H3991109821">
         <span class="h2">
          Continue MOUD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Continuing MOUD postpartum is important to support retention in treatment of OUD and prevent return to use.
        </p>
        <p>
         Overdose is a leading cause of pregnancy-related deaths in the year following delivery [
         <a href="#rid97">
          97
         </a>
         ]. In a population-based study of individuals with Medicaid insurance in the United States from 2006 to 2013, individuals with OUD had higher incidences of both postpartum opioid overdose death (118 versus 5.4 per 100,000 deliveries) and all-cause postpartum death (316 versus 51.1 per 100,000 deliveries) compared with the general obstetric population in this database [
         <a href="#rid98">
          98
         </a>
         ]. Postpartum use of MOUD was associated with a 60 percent reduction in the odds of opioid overdose death (odds ratio [OR] 0.4, 95% CI 0.1-0.9). However, MOUD is often discontinued. A study using data from the Massachusetts Department of Public Health found MOUD discontinuation in 36 percent of patients and &lt;4 months of treatment increased the likelihood of postpartum discontinuation [
         <a href="#rid99">
          99,100
         </a>
         ]. In another study, treatment dropout was related to ongoing use of illicit substances, particularly benzodiazepines [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p>
         Given the substantial obstacles present in the postpartum period (eg, postpartum mood disorders, stress of newborn care, child protective services involvement), a plan should be in place to ensure that the patient receives adequate MOUD and does not delay follow-up with their OUD treatment provider. This is particularly important for patients newly engaged in treatment.
        </p>
        <p class="headingAnchor" id="H1279532393">
         <span class="h2">
          Postpartum methadone and buprenorphine dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The patient's usual oral
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         or
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         dose is continued postpartum to prevent withdrawal. Dosing is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/87238.html" rel="external">
          "Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy", section on 'Intrapartum and postpartum methadone dosing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/87238.html" rel="external">
          "Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy", section on 'Intrapartum and postpartum buprenorphine dosing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2259949333">
         <span class="h2">
          Pain management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Postpartum pain should be managed using a multimodal approach that starts with nonopioid analgesia, when possible, in addition to standard postpartum pain control measures and MOUD [
         <a href="#rid12">
          12
         </a>
         ]. Persistent pain despite these measures may be treated with opioids (eg,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         ,
         <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">
          hydromorphone
         </a>
         ).
        </p>
        <p>
         The goal of postpartum pain control is subjective pain relief without excessive side effects. Patients should be informed that while individual experience varies, antenatal opioid use may interfere with postpartum pain control and increase postpartum opioid requirements, particularly after cesarean birth. Opioid requirements may be 30 to 100 percent higher than those in opioid-naïve patients; sometimes even greater increases are required [
         <a href="#rid95">
          95,102
         </a>
         ]. Significant interpatient variability in opioid dose requirements makes it impossible to precisely predict the opioid dose necessary to control postpartum pain [
         <a href="#rid56">
          56,95
         </a>
         ]. The additional difficulty of continued opioid use may prevent providers from having a full appreciation of a patient's total opioid dose [
         <a href="#rid55">
          55
         </a>
         ]. Smoking is very common in individuals with OUD and is associated with increased postoperative narcotic requirements [
         <a href="#rid103">
          103
         </a>
         ]. Psychologic conditions, which are also prevalent in this population, independently predict poor pain control [
         <a href="#rid92">
          92,95,104
         </a>
         ]. As with antepartum pain management, tight binding to the mu-opioid receptor, cross tolerance, and opioid-induced hyperalgesia result in increased pain and the need for higher than usual doses of opioid analgesics. Management of acute pain is more challenging in patients taking
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         than those taking
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         because of its higher affinity for the mu-opioid receptor.
        </p>
        <p>
         Specific approaches to pain management after vaginal and cesarean birth are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/130304.html" rel="external">
          "Obstetric anesthesia for patients with opioid use disorder or opioid tolerance", section on 'Postpartum analgesia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4219055642">
         <span class="h2">
          Postpartum monitoring and counseling
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Frequent maternal follow-up for recovery support, relapse prevention, and assessment of other preexisting mental health disorders is important after delivery. Patients should be seen in the office and/or contacted by phone multiple times, ideally over the first year postpartum. They are at particularly high risk of relapse postpartum due to multiple stressors, including changes in insurance coverage and access to care, demands of newborn care, exacerbation of underlying mental health conditions, and the stress of involvement of child protective services and the threat of losing custody of the child [
         <a href="#rid105">
          105
         </a>
         ]. Large, population-based retrospective cohort studies of the general obstetric population have reported high rates of overdose 7 to 12 months after delivery [
         <a href="#rid106">
          106,107
         </a>
         ]. Risk factors for postpartum overdose included maternal diagnosis of OUD and prior non-fatal overdose [
         <a href="#rid107">
          107
         </a>
         ]. Longer duration of MOUD during pregnancy appears to increase the chances of MOUD continuation postpartum and appears to protect against overdose [
         <a href="#rid13">
          13,100
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The Alliance for Innovation on Maternal Health Program (AIM) has developed a maternal safety bundle on obstetric care of patients with OUD. The bundle includes recommendations for breastfeeding and lactation support for all patients on pharmacotherapy; provides immediate postpartum, long-acting reversible contraception (LARC) when desired; and facilitates referrals to providers (eg, social work, psychiatry, and infectious disease) for management of comorbid conditions. It is important to ensure a "warm hand off" (ie, direct introduction of the client to the behavioral health provider) to the clinician who will coordinate care going forward after the birth [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a comorbid mental health disorder has been diagnosed, follow-up with an appropriate provider should be arranged. Postpartum screening for depression is recommended for all patients. (See
         <a class="medical medical_review" href="/z/d/html/1704.html" rel="external">
          "Postpartum unipolar major depression: Epidemiology, clinical features, assessment, and diagnosis", section on 'Screening'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Postpartum contraceptive counseling is particularly important in this population due to a high rate of unplanned pregnancy [
         <a href="#rid109">
          109
         </a>
         ]. The option of an immediate postpartum contraceptive (eg, LARC) should be discussed prior to hospital discharge. (See
         <a class="medical medical_review" href="/z/d/html/6708.html" rel="external">
          "Contraception: Postpartum counseling and methods"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Provide information on neonatal abstinence syndrome and newborn care. (See
         <a class="medical medical_review" href="/z/d/html/5016.html" rel="external">
          "Prenatal substance exposure and neonatal abstinence syndrome (NAS): Management and outcomes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Involve appropriate partners (eg, social workers, case managers, peer recovery coaches) to assist patients and families in the development of a plan of safe care for mother and infant [
         <a href="#rid110">
          110
         </a>
         ]. Families should be referred to programs providing perinatal and infant health services, where available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Breastfeeding should be encouraged, with lactation support. (See
         <a class="medical medical_review" href="/z/d/html/87238.html" rel="external">
          "Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy", section on 'Breastfeeding'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/87238.html" rel="external">
          "Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy", section on 'Breastfeeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h1">
          MEDICALLY ASSISTED OPIOID WITHDRAWAL
         </span>
        </p>
        <p class="headingAnchor" id="H1124894499">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medically assisted opioid withdrawal (also called medically supervised opioid withdrawal, detoxification, or medical withdrawal) followed by psychosocial (nonmedication) treatment, although possible, should be used rarely due to the high percentage of recidivism: A systematic review found that relapse rates varied from 0 to 100 percent across studies depending on whether data from participants who did not complete detoxification or who were lost to follow-up were included in analyses [
         <a href="#rid22">
          22
         </a>
         ]. The overall quality of the evidence was fair to poor, and few studies followed patients past delivery. Although historically concerns have been raised that medically assisted withdrawal could lead to fetal demise based on one case report [
         <a href="#rid111">
          111
         </a>
         ] and the results of serial amniocentesis for amniotic fluid catecholamines, thought to be indicative of fetal stress [
         <a href="#rid112">
          112
         </a>
         ], the systematic review did not find higher rates of fetal demise in patients undergoing medically assisted withdrawal.
        </p>
        <p>
         For patients declining medication for OUD (MOUD), medically assisted withdrawal may be offered, but requires a thorough discussion about the risks of relapse and the need for consistent psychosocial support during and following the withdrawal process [
         <a href="#rid12">
          12
         </a>
         ]. For patients initially declining MOUD, the process of medically assisted opioid withdrawal presents an opportunity to reconsider and switch to MOUD, particularly with a longer tapering schedule. In one study, 42 percent of patients undergoing a seven-day
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         taper transitioned to methadone treatment versus 11 percent undergoing a three-day taper [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2660869695">
         <span class="h2">
          Candidates
         </span>
         <span class="headingEndMark">
          —
         </span>
         Indications for medically assisted opioid withdrawal during pregnancy include inability or declining to participate in long-term MOUD, patient request, and/or when MOUD is unavailable [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2988579262">
         <span class="h2">
          Procedure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medically assisted opioid withdrawal should only be undertaken at a center familiar with this procedure in pregnancy and after obtaining informed consent. Candidates should undergo an ultrasound examination to look for preexisting signs of fetuses at risk for adverse outcome, such as oligohydramnios or fetal growth restriction, which would preclude medically assisted withdrawal [
         <a href="#rid14">
          14,113
         </a>
         ].
        </p>
        <p>
         Patients not on
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         should be admitted for methadone initiation and stabilization, after which the methadone dose can be slowly tapered at a rate of up to 20 percent every three days. A more gradual approach of lowering the dose 2 to 5 mg every 6 to 16 days has also been used [
         <a href="#rid71">
          71,112
         </a>
         ]. Patients already taking methadone can be tapered to 20 mg per day as outpatients and then admitted for further tapering and discontinuation of the drug. A detailed description of the procedure in nonpregnant patients is available separately. We would avoid accelerated protocols during pregnancy as safety is unknown. (See
         <a class="medical medical_review" href="/z/d/html/7808.html" rel="external">
          "Opioid withdrawal: Medically supervised withdrawal during treatment for opioid use disorder"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          Buprenorphine
         </a>
         can also be used for medically assisted opioid withdrawal. Hospital admission is not a requirement if the patient can be cared for by a buprenorphine provider. Before beginning buprenorphine, it is important to remember that it requires 12 to 24 hours of abstention from short-acting opioids and 48 to 72 hours abstention from
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         , and the patient should have mild to moderate opioid withdrawal with documentation of objective signs of withdrawal. For patients who cannot achieve this interval of abstention, methadone may be a better option. Alternatively, utilizing a microdosing protocol for buprenorphine may be effective for these patients [
         <a href="#rid114">
          114
         </a>
         ]. We generally recommend not switching patients already on methadone to buprenorphine, as this will precipitate withdrawal. However, in shared decision-making with the patient, if this transition is desired, it may be achieved with a microdosing protocol, although microdosing for this purpose has only been studied outside of pregnancy [
         <a href="#rid115">
          115,116
         </a>
         ].
        </p>
        <p>
         We have no experience with use of other drugs for this purpose in pregnancy, and would specifically avoid
         <a class="drug drug_general" data-topicid="117925" href="/z/d/drug information/117925.html" rel="external">
          lofexidine
         </a>
         or
         <a class="drug drug_general" data-topicid="9999" href="/z/d/drug information/9999.html" rel="external">
          tizanidine
         </a>
         because they can significantly lower blood pressure.
        </p>
        <p>
         Medically assisted opioid withdrawal can take place in any trimester, although most authorities avoid the procedure in the first and late third trimester. If the reason for medical withdrawal is prevention of neonatal withdrawal, the medical withdrawal treatment should be completed two months before delivery [
         <a href="#rid117">
          117
         </a>
         ]. We suggest daily nonstress tests during the withdrawal process for pregnancies in the late second and third trimester.
        </p>
        <p class="headingAnchor" id="H198208672">
         <span class="h2">
          Pregnancy outcome
         </span>
         <span class="headingEndMark">
          —
         </span>
         The best evidence suggests that there is no increased risk of harm to the fetus [
         <a href="#rid23">
          23,113,118,119
         </a>
         ], although miscarriages, preterm births, meconium passage, stillbirths, and elevated amniotic fluid epinephrine and norepinephrine levels have been reported in case reports [
         <a href="#rid111">
          111,112
         </a>
         ]. Systematic reviews have reported that fetal loss and preterm birth rates were similar among patients who did and did not undergo medically assisted withdrawal [
         <a href="#rid22">
          22,23
         </a>
         ]. A detailed illustrative example is described below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One large series of outcomes of medical withdrawal in 301 patients in Tennessee divided them into four groups: group 1 (involuntary because of incarceration; n = 108), group 2 (five to eight days of inpatient detoxification with an outpatient behavioral health follow-up; n = 23), group 3 (five to eight days of inpatient detoxification without an outpatient behavioral health follow-up; n = 77), and group 4 (8 to 16 weeks of outpatient detoxification with an outpatient behavioral health follow-up; n = 93) [
         <a href="#rid119">
          119
         </a>
         ]. Major findings were:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Two fetal deaths occurred, both to patients in group 1. The first occurred in the setting of abruption at 18 weeks, 8 weeks after detoxification, and the second occurred at 34 weeks in the setting of congenital anomalies and hydrops, following detoxification at 12 weeks. In both cases, urine drug screening was negative at the time of demise.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Relapse occurred in 17 to 23 percent of patients in groups 1, 2, and 4, and 74 percent of patients in group 3.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         31 percent of infants were treated for neonatal abstinence syndrome, and all were delivered of mothers with evidence of relapse (eg, maternal admission, positive urine drug screening, meconium in amniotic fluid).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The authors could not assess the incidence of fetal distress because fetal monitoring was not routinely performed during opioid withdrawal.
        </p>
        <p>
        </p>
        <p>
         There are no long-term follow-up studies of children born to mothers who underwent opioid withdrawal during pregnancy.
        </p>
        <p>
         We agree with the American College of Obstetricians and Gynecologists' recommendation for additional research to assess the safety, efficacy, and long-term outcomes of medically assisted withdrawal [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H722326671">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113643.html" rel="external">
          "Society guideline links: Opioid use disorder and withdrawal"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/118165.html" rel="external">
          "Society guideline links: Substance misuse in pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Candidates for MOUD
         </strong>
         – Pregnant individuals with opioid use disorder (OUD) should be offered medication for OUD (MOUD). (See
         <a class="local">
          'Candidates for MOUD'
         </a>
         above.) MOUD is preferable to medical withdrawal followed by medication-free psychosocial treatment because medical withdrawal is associated with a high percentage of recidivism. (See
         <a class="local">
          'MOUD or medically assisted withdrawal?'
         </a>
         above and
         <a class="local">
          'Medically assisted opioid withdrawal'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Options for MOUD
         </strong>
         – For pregnant individuals who are identified as candidates for MOUD, we consider several factors when counseling about options  (
         <a class="graphic graphic_table graphicRef87713" href="/z/d/graphic/87713.html" rel="external">
          table 3
         </a>
         ); the choice of medication (
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         versus
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         ) is a shared decision. (See
         <a class="local">
          'Our approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pretreatment evaluation
         </strong>
         – Pretreatment maternal evaluation in patients with OUD should include a detailed psychosocial history, screening for sexually transmitted and other infections, and sonographic examination of the pregnancy. (See
         <a class="local">
          'Pretreatment maternal evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnancy management
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Fetal monitoring
         </strong>
         – After initial stabilization and initiation of pharmacotherapy, we do not obtain outpatient antepartum fetal testing (nonstress test, biophysical profile) in patients who consistently demonstrate good compliance by negative urine toxicology screens and have no standard indications for fetal surveillance. However, for patients with evidence of ongoing substance use, or patients who have other indications for fetal surveillance (eg, preeclampsia, fetal growth restriction), weekly or twice weekly testing during the third trimester is reasonable. (See
         <a class="local">
          'Antenatal fetal monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Monitoring fetal growth
         </strong>
         – There is no consistent effect of MOUD on fetal growth; however, we perform an ultrasound to assess fetal growth between 28 and 32 weeks of gestation. Growth is more likely to be a concern in those patients with ongoing illicit drug use. If there is a clinical suspicion of fetal growth restriction (eg, lagging fundal height), an ultrasound examination is indicated and management is the same as for any pregnancy complicated by impaired fetal growth. (See
         <a class="local">
          'Assessment for growth restriction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pain management
         </strong>
         – Neuraxial anesthesia is a common approach to pain management during labor and delivery in the general obstetric population and a good option for patients on MOUD. Pain control in patients with OUD is similar to that in patients without this disorder and include both pharmacologic (nonopioid and opioid) and nonpharmacologic approaches; however, mixed agonist and antagonist opioid analgesics, such as
         <a class="drug drug_general" data-topicid="9753" href="/z/d/drug information/9753.html" rel="external">
          pentazocine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9676" href="/z/d/drug information/9676.html" rel="external">
          nalbuphine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9179" href="/z/d/drug information/9179.html" rel="external">
          butorphanol
         </a>
         , should not be administered, as they may displace
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         from the mu receptor and precipitate acute withdrawal. Acute intrapartum and postpartum pain should not be treated with additional doses of methadone or
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         . (See
         <a class="local">
          'Analgesia and anesthesia'
         </a>
         above and
         <a class="local">
          'Pain management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postpartum care
         </strong>
         – Patients are at particularly high risk of relapse to opioid use postpartum due to multiple stressors. Close monitoring and continuing MOUD postpartum are important to support retention in treatment of OUD and prevent return to use. As in all postpartum patients, screening for depression and offering postpartum contraception is important. (See
         <a class="local">
          'Postpartum monitoring and counseling'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24987292">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Susan M Weiner, PhD, MSN, RNC, CNS, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs. Treatment Improvement Protocol (TIP) Series 43. DHHS publication no. (SMA) 05-4048. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2005. https://store.samhsa.gov/shin/content//SMA12-4214/SMA12-4214.pdf (Accessed on November 01, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy. Obstet Gynecol 2017; 130:e81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan JP, Choi S, Hong JS, et al. Recovery coaches and substance exposed births: an experiment in child welfare. Child Abuse Negl 2008; 32:1072.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008; 96:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piske M, Homayra F, Min JE, et al. Opioid Use Disorder and Perinatal Outcomes. Pediatrics 2021; 148.
          </a>
         </li>
         <li class="breakAll">
          Medications development for the treatment of pregnant addicts and their infants. National Institutes of Drug Abuse, Monograph 149, 1995. www.nida.nih.gov/pdf/monographs/download149.html (Accessed on March 18, 2009).
         </li>
         <li class="breakAll">
          http://consensus.nih.gov/1997/1998TreatOpiateAddiction108html.htm (Accessed on March 19, 2009).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones HE, O'Grady KE, Malfi D, Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict 2008; 17:372.
          </a>
         </li>
         <li class="breakAll">
          https://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/asam-national-practice-guideline-supplement.pdf (Accessed on July 25, 2018).
         </li>
         <li class="breakAll">
          ASAM national practice guideline for the use of medications in the treatment of addiction involving opioid use https://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/asam-national-practice-guideline-supplement.pdf (Accessed on July 25, 2018).
         </li>
         <li class="breakAll">
          Substance Abuse and Mental Health Services Administration. Clinical Guidance for Treating Pregnant and
Parenting Women With Opioid Use Disorder and Their Infants. HHS Publication No. (SMA) 18-5054. Rockville,
MD: Substance Abuse and Mental Health Services Administration, 2018.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ecker J, Abuhamad A, Hill W, et al. Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine. Am J Obstet Gynecol 2019; 221:B5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krans EE, Kim JY, Chen Q, et al. Outcomes associated with the use of medications for opioid use disorder during pregnancy. Addiction 2021; 116:3504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dashe JS, Sheffield JS, Olscher DA, et al. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol 2002; 100:1244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ostrea EM, Chavez CJ, Strauss ME. A study of factors that influence the severity of neonatal narcotic withdrawal. J Pediatr 1976; 88:642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madden JD, Chappel JN, Zuspan F, et al. Observation and treatment of neonatal narcotic withdrawal. Am J Obstet Gynecol 1977; 127:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harper RG, Solish G, Feingold E, et al. Maternal ingested methadone, body fluid methadone, and the neonatal withdrawal syndrome. Am J Obstet Gynecol 1977; 129:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strauss ME, Andresko M, Stryker JC, Wardell JN. Relationship of neonatal withdrawal to maternal methadone dose. Am J Drug Alcohol Abuse 1976; 3:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen TS, Pippenger CE. Pharmacologic observations on the neonatal withdrawal syndrome. J Pediatr 1976; 88:1044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinha C, Ohadike P, Carrick P, et al. Neonatal outcome following maternal opiate use in late pregnancy. Int J Gynaecol Obstet 2001; 74:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maas U, Kattner E, Weingart-Jesse B, et al. Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy. J Perinat Med 1990; 18:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terplan M, Laird HJ, Hand DJ, et al. Opioid Detoxification During Pregnancy: A Systematic Review. Obstet Gynecol 2018; 131:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Towers CV, Terry P, Rackley B, et al. Fetal Outcomes with Detoxification from Opioid Drugs during Pregnancy: A Systematic Review. Am J Perinatol 2020; 37:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunne LM, Grönbladh L. The Swedish methadone maintenance program: a controlled study. Drug Alcohol Depend 1981; 7:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; :CD002209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mullins N, Galvin SL, Ramage M, et al. Buprenorphine and Naloxone Versus Buprenorphine for Opioid Use Disorder in Pregnancy: A Cohort Study. J Addict Med 2020; 14:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Link HM, Jones HE, Miller LA, et al. Buprenorphine-naloxone use in pregnancy: a subgroup analysis of medication to treat opioid use disorder. Am J Obstet Gynecol MFM 2021; 3:100369.
          </a>
         </li>
         <li class="breakAll">
          http://www.who.int/substance_abuse/activities/pregnancy_substance_use/en/.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minozzi S, Amato L, Jahanfar S, et al. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev 2020; 11:CD006318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nanda S, Brant R, Regier M, Yossuck P. Buprenorphine: a new player in neonatal withdrawal syndrome. W V Med J 2015; 111:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krans EE, Bogen D, Richardson G, et al. Factors associated with buprenorphine versus methadone use in pregnancy. Subst Abus 2016; 37:550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finnegan LP, Hagan T, Kaltenbach KA. Scientific foundation of clinical practice: opiate use in pregnant women. Bull N Y Acad Med 1991; 67:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miles J, Sugumar K, Macrory F, et al. Methadone-exposed newborn infants: outcome after alterations to a service for mothers and infants. Child Care Health Dev 2007; 33:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jansson LM, Svikis D, Lee J, et al. Pregnancy and addiction. A comprehensive care model. J Subst Abuse Treat 1996; 13:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zedler BK, Mann AL, Kim MM, et al. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. Addiction 2016; 111:2115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bell JR, Butler B, Lawrance A, et al. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009; 104:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA 2001; 285:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suarez EA, Huybrechts KF, Straub L, et al. Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy. N Engl J Med 2022; 387:2033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363:2320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brogly SB, Saia KA, Walley AY, et al. Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis. Am J Epidemiol 2014; 180:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minozzi S, Amato L, Bellisario C, et al. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev 2013; :CD006318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newman RG, Gevertz SG. Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy. J Addict Dis 2011; 30:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005; 79:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006; 101:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones HE, Heil SH, Baewert A, et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction 2012; 107 Suppl 1:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008; :CD002207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelty E, Hulse G. A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates. Drugs 2017; 77:1211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Towers CV, Katz E, Weitz B, Visconti K. Use of naltrexone in treating opioid use disorder in pregnancy. Am J Obstet Gynecol 2020; 222:83.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wachman EM, Saia K, Miller M, et al. Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects. Clin Ther 2019; 41:1681.
          </a>
         </li>
         <li class="breakAll">
          Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. DHHS publication; no. (SMA)18–5054. U.S. Substance Abuse and Mental Health Services Administration. Rockville (MD): Department of Health and Human Services; 2018.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smid MC, Charles JE, Gordon AJ, Wright TE. Use of Kratom, an Opioid-like Traditional Herb, in Pregnancy. Obstet Gynecol 2018; 132:926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright ME, Ginsberg C, Parkison AM, et al. Outcomes of mothers and newborns to prenatal exposure to kratom: a systematic review. J Perinatol 2021; 41:1236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright TE, Terplan M, Ondersma SJ, et al. The role of screening, brief intervention, and referral to treatment in the perinatal period. Am J Obstet Gynecol 2016; 215:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones HE, Deppen K, Hudak ML, et al. Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers. Am J Obstet Gynecol 2014; 210:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehta V, Langford RM. Acute pain management for opioid dependent patients. Anaesthesia 2006; 61:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huxtable CA, Roberts LJ, Somogyi AA, MacIntyre PE. Acute pain management in opioid-tolerant patients: a growing challenge. Anaesth Intensive Care 2011; 39:804.
          </a>
         </li>
         <li class="breakAll">
          Substance Abuse Confidentialiy Regulations https://www.samphsa.gov/about-us/who-are-we/laws-regulations/confidentiality-regulations-faqs (Accessed on August 20, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dube SR, Felitti VJ, Dong M, et al. Childhood abuse, neglect, and household dysfunction and the risk of illicit drug use: the adverse childhood experiences study. Pediatrics 2003; 111:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson AJ, Jones CW. Opioid Use Disorders and Pregnancy. Obstet Gynecol Clin North Am 2018; 45:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krans EE, Cochran G, Bogen DL. Caring for Opioid-dependent Pregnant Women: Prenatal and Postpartum Care Considerations. Clin Obstet Gynecol 2015; 58:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holbrook A, Kaltenbach K. Co-occurring psychiatric symptoms in opioid-dependent women: the prevalence of antenatal and postnatal depression. Am J Drug Alcohol Abuse 2012; 38:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarthy JJ, Leamon MH, Parr MS, Anania B. High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. Am J Obstet Gynecol 2005; 193:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown HL, Britton KA, Mahaffey D, et al. Methadone maintenance in pregnancy: a reappraisal. Am J Obstet Gynecol 1998; 179:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baxter FR, Nerhood R, Chaffin D. Characterization of babies discharged from Cabell Huntington Hospital during the calendar year 2005 with the diagnoses of neonatal abstinence syndrome. W V Med J 2009; 105:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones HE, Heil SH, O'Grady KE, et al. Smoking in pregnant women screened for an opioid agonist medication study compared to related pregnant and non-pregnant patient samples. Am J Drug Alcohol Abuse 2009; 35:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choo RE, Huestis MA, Schroeder JR, et al. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend 2004; 75:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winklbaur B, Baewert A, Jagsch R, et al. Association between prenatal tobacco exposure and outcome of neonates born to opioid-maintained mothers. Implications for treatment. Eur Addict Res 2009; 15:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakstad B, Sarfi M, Welle-Strand GK, Ravndal E. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study. Eur Addict Res 2009; 15:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jarlenski MP, Paul NC, Krans EE. Polysubstance Use Among Pregnant Women With Opioid Use Disorder in the United States, 2007-2016. Obstet Gynecol 2020; 136:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almario CV, Seligman NS, Dysart KC, et al. Risk factors for preterm birth among opiate-addicted gravid women in a methadone treatment program. Am J Obstet Gynecol 2009; 201:326.e1.
          </a>
         </li>
         <li class="breakAll">
          New South Wales methadone maintenance treatment clinical practice guidelines. State health publication, NSW Health Department; Sydney, 1999.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilbourne P, Wallerstedt C, Dorato V, Curet LB. Clinical management of methadone dependence during pregnancy. J Perinat Neonatal Nurs 2001; 14:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connaughton JF, Reeser D, Schut J, Finnegan LP. Perinatal addiction: outcome and management. Am J Obstet Gynecol 1977; 129:679.
          </a>
         </li>
         <li class="breakAll">
          Kaye M, Chasnoff I. Substance abuse in pregnancy. In: High-risk Pregnancy, a Team Approach, Knuppel R, Drukker J (Eds), WBS, Philadelphia 1993.
         </li>
         <li>
          <a class="nounderline abstract_t">
           American College of Obstetricians and Gynecologists Committee on Health Care for Underserved Women. AGOG Committee Opinion No. 473: substance abuse reporting and pregnancy: the role of the obstetrician-gynecologist. Obstet Gynecol 2011; 117:200. Reaffirmed 2022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee opinion no. 633: Alcohol abuse and other substance use disorders: ethical issues in obstetric and gynecologic practice. Obstet Gynecol 2015; 125:1529. Reaffirmed 2022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 106: Intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. Obstet Gynecol 2009; 114:192. Reaffirmed 2021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Archie CL, Lee MI, Sokol RJ, Norman G. The effects of methadone treatment on the reactivity of the nonstress test. Obstet Gynecol 1989; 74:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cejtin HE, Mills A, Swift EL. Effect of methadone on the biophysical profile. J Reprod Med 1996; 41:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine AB, Rebarber A. Methadone maintenance treatment and the nonstress test. J Perinatol 1995; 15:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salisbury AL, Coyle MG, O'Grady KE, et al. Fetal assessment before and after dosing with buprenorphine or methadone. Addiction 2012; 107 Suppl 1:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anyaegbunam A, Tran T, Jadali D, et al. Assessment of fetal well-being in methadone-maintained pregnancies: abnormal nonstress tests. Gynecol Obstet Invest 1997; 43:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jansson LM, Dipietro J, Elko A. Fetal response to maternal methadone administration. Am J Obstet Gynecol 2005; 193:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wouldes TA, Roberts AB, Pryor JE, et al. The effect of methadone treatment on the quantity and quality of human fetal movement. Neurotoxicol Teratol 2004; 26:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramirez-Cacho WA, Flores S, Schrader RM, et al. Effect of chronic maternal methadone therapy on intrapartum fetal heart rate patterns. J Soc Gynecol Investig 2006; 13:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jansson LM, Dipietro JA, Velez M, et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicol Teratol 2011; 33:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jansson LM, Velez M, McConnell K, et al. Maternal buprenorphine treatment and fetal neurobehavioral development. Am J Obstet Gynecol 2017; 216:529.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotelchuck M, Cheng ER, Belanoff C, et al. The Prevalence and Impact of Substance Use Disorder and Treatment on Maternal Obstetric Experiences and Birth Outcomes Among Singleton Deliveries in Massachusetts. Matern Child Health J 2017; 21:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hulse GK, Milne E, English DR, Holman CD. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction 1997; 92:1571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam SK, To WK, Duthie SJ, Ma HK. Narcotic addiction in pregnancy with adverse maternal and perinatal outcome. Aust N Z J Obstet Gynaecol 1992; 32:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fulroth R, Phillips B, Durand DJ. Perinatal outcome of infants exposed to cocaine and/or heroin in utero. Am J Dis Child 1989; 143:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carroll IR, Angst MS, Clark JD. Management of perioperative pain in patients chronically consuming opioids. Reg Anesth Pain Med 2004; 29:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med 2006; 144:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernandez M, Birnbach DJ, Van Zundert AA. Anesthetic management of the illicit-substance-using patient. Curr Opin Anaesthesiol 2005; 18:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitra S, Sinatra RS. Perioperative management of acute pain in the opioid-dependent patient. Anesthesiology 2004; 101:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer M, Wagner K, Benvenuto A, et al. Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy. Obstet Gynecol 2007; 110:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayes L. Postpartum Relapse Prevention: The Family Physician's Role. Am Fam Physician 2020; 101:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suarez EA, Huybrechts KF, Straub L, et al. Postpartum Opioid-Related Mortality in Patients With Public Insurance. Obstet Gynecol 2023; 141:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiff DM, Nielsen TC, Hoeppner BB, et al. Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder. Am J Obstet Gynecol 2021; 225:424.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jarlenski M, Chen Q, Gao A, et al. Association of Duration of Methadone or Buprenorphine Use During Pregnancy With Risk of Nonfatal Drug Overdose Among Pregnant Persons With Opioid Use Disorder in the US. JAMA Netw Open 2022; 5:e227964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ray-Griffith S, Tharp E, Coker JL, et al. Buprenorphine Medication for Opioid Use Disorder: A Study of Factors Associated With Postpartum Treatment Retention. Am J Addict 2021; 30:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones HE, Johnson RE, Milio L. Post-cesarean pain management of patients maintained on methadone or buprenorphine. Am J Addict 2006; 15:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Creekmore FM, Lugo RA, Weiland KJ. Postoperative opiate analgesia requirements of smokers and nonsmokers. Ann Pharmacother 2004; 38:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Höflich AS, Langer M, Jagsch R, et al. Peripartum pain management in opioid dependent women. Eur J Pain 2012; 16:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gopman S. Prenatal and postpartum care of women with substance use disorders. Obstet Gynecol Clin North Am 2014; 41:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiff DM, Nielsen T, Terplan M, et al. Fatal and Nonfatal Overdose Among Pregnant and Postpartum Women in Massachusetts. Obstet Gynecol 2018; 132:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen T, Bernson D, Terplan M, et al. Maternal and infant characteristics associated with maternal opioid overdose in the year following delivery. Addiction 2020; 115:291.
          </a>
         </li>
         <li class="breakAll">
          Obstetric care for women with opioid use disorder. https://safehealthcareforeverywoman.org/patient-safety-bundles/obstetric-care-for-women-with-opioid-use-disorder/#link_acc-1-4-d (Accessed on October 03, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terplan M, Hand DJ, Hutchinson M, et al. Contraceptive use and method choice among women with opioid and other substance use disorders: A systematic review. Prev Med 2015; 80:23.
          </a>
         </li>
         <li class="breakAll">
          https://safehealthcareforeverywoman.org/patient-safety-bundles/obstetric-care-for-women-with-opioid-use-disorder/#link_acc-1-4-d (Accessed on July 31, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rementeriá JL, Nunag NN. Narcotic withdrawal in pregnancy: stillbirth incidence with a case report. Am J Obstet Gynecol 1973; 116:1152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuspan FP, Gumpel JA, Mejia-Zelaya A, et al. Fetal stress from methadone withdrawal. Am J Obstet Gynecol 1975; 122:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dashe JS, Jackson GL, Olscher DA, et al. Opioid detoxification in pregnancy. Obstet Gynecol 1998; 92:854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galati BM, Carter EB, Perez M, et al. Buprenorphine Patch as a Bridge to Sublingual Treatment of Opioid Use Disorder in Pregnancy. Obstet Gynecol 2021; 137:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed S, Bhivandkar S, Lonergan BB, Suzuki J. Microinduction of Buprenorphine/Naloxone: A Review of the Literature. Am J Addict 2021; 30:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Aquino JP, Fairgrieve C, Klaire S, Garcia-Vassallo G. Rapid Transition From Methadone to Buprenorphine Utilizing a Micro-dosing Protocol in the Outpatient Veteran Affairs Setting. J Addict Med 2020; 14:e271.
          </a>
         </li>
         <li class="breakAll">
          Guidelines for the treatment of drug addiction, 2001. http://www.emcdda.europa.eu/best-practice/standards/treatment (Accessed on April 12, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blinick G, Wallach RC, Jerez E. Pregnancy in narcotics addicts treated by medical withdrawal. The methadone detoxification program. Am J Obstet Gynecol 1969; 105:997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bell J, Towers CV, Hennessy MD, et al. Detoxification from opiate drugs during pregnancy. Am J Obstet Gynecol 2016; 215:374.e1.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4790 Version 76.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://store.samhsa.gov/shin/content//SMA12-4214/SMA12-4214.pdf" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs. Treatment Improvement Protocol (TIP) Series 43. DHHS publication no. (SMA) 05-4048. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2005. https://store.samhsa.gov/shin/content//SMA12-4214/SMA12-4214.pdf (Accessed on November 01, 2017).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28742676" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19036450" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Recovery coaches and substance exposed births: an experiment in child welfare.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18355989" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34479983" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Opioid Use Disorder and Perinatal Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34479983" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Opioid Use Disorder and Perinatal Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34479983" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Opioid Use Disorder and Perinatal Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18770079" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18770079" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18770079" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18770079" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30928567" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34033170" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Outcomes associated with the use of medications for opioid use disorder during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12468169" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Relationship between maternal methadone dosage and neonatal withdrawal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1255327" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A study of factors that influence the severity of neonatal narcotic withdrawal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/831502" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Observation and treatment of neonatal narcotic withdrawal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/910821" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Maternal ingested methadone, body fluid methadone, and the neonatal withdrawal syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1032747" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Relationship of neonatal withdrawal to maternal methadone dose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1271174" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Pharmacologic observations on the neonatal withdrawal syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11543747" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Neonatal outcome following maternal opiate use in late pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2366131" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29630016" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Opioid Detoxification During Pregnancy: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31104311" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Fetal Outcomes with Detoxification from Opioid Drugs during Pregnancy: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7261900" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The Swedish methadone maintenance program: a controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19588333" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31567599" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Buprenorphine and Naloxone Versus Buprenorphine for Opioid Use Disorder in Pregnancy: A Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33831585" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Buprenorphine-naloxone use in pregnancy: a subgroup analysis of medication to treat opioid use disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33831585" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Buprenorphine-naloxone use in pregnancy: a subgroup analysis of medication to treat opioid use disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33165953" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Maintenance agonist treatments for opiate-dependent pregnant women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25665273" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Buprenorphine: a new player in neonatal withdrawal syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26914546" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Factors associated with buprenorphine versus methadone use in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1868275" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Scientific foundation of clinical practice: opiate use in pregnant women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17291325" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Methadone-exposed newborn infants: outcome after alterations to a service for mothers and infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9076650" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Pregnancy and addiction. A comprehensive care model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27223595" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19443138" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Comparing overdose mortality associated with methadone and buprenorphine treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11150107" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Deaths attributable to methadone vs buprenorphine in France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36449419" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21142534" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Neonatal abstinence syndrome after methadone or buprenorphine exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25150272" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24366859" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Maintenance agonist treatments for opiate-dependent pregnant women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22026523" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15943939" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16445556" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23106923" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18425880" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28536981" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31376396" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Use of naltrexone in treating opioid use disorder in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31358302" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31358302" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30204686" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Use of Kratom, an Opioid-like Traditional Herb, in Pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33589723" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Outcomes of mothers and newborns to prenatal exposure to kratom: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27373599" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : The role of screening, brief intervention, and referral to treatment in the perinatal period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24120973" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16480353" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Acute pain management for opioid dependent patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21970125" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Acute pain management in opioid-tolerant patients: a growing challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21970125" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Acute pain management in opioid-tolerant patients: a growing challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12612237" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Childhood abuse, neglect, and household dysfunction and the risk of illicit drug use: the adverse childhood experiences study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29747726" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Opioid Use Disorders and Pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25775440" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Caring for Opioid-dependent Pregnant Women: Prenatal and Postpartum Care Considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22783870" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Co-occurring psychiatric symptoms in opioid-dependent women: the prevalence of antenatal and postnatal depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16150249" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9731853" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Methadone maintenance in pregnancy: a reappraisal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19271694" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Characterization of babies discharged from Cabell Huntington Hospital during the calendar year 2005 with the diagnoses of neonatal abstinence syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20180667" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Smoking in pregnant women screened for an opioid agonist medication study compared to related pregnant and non-pregnant patient samples.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15283946" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19420947" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Association between prenatal tobacco exposure and outcome of neonates born to opioid-maintained mothers. Implications for treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19332991" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32769641" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Polysubstance Use Among Pregnant Women With Opioid Use Disorder in the United States, 2007-2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19631928" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Risk factors for preterm birth among opiate-addicted gravid women in a methadone treatment program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19631928" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Risk factors for preterm birth among opiate-addicted gravid women in a methadone treatment program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11930521" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Clinical management of methadone dependence during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/303464" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Perinatal addiction: outcome and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/303464" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Perinatal addiction: outcome and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21173672" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : AGOG Committee Opinion No. 473: substance abuse reporting and pregnancy: the role of the obstetrician-gynecologist.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26000541" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Committee opinion no. 633: Alcohol abuse and other substance use disorders: ethical issues in obstetric and gynecologic practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19546798" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : ACOG Practice Bulletin No. 106: Intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2748062" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : The effects of methadone treatment on the reactivity of the nonstress test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8951131" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Effect of methadone on the biophysical profile.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7666273" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Methadone maintenance treatment and the nonstress test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23106925" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Fetal assessment before and after dosing with buprenorphine or methadone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9015694" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Assessment of fetal well-being in methadone-maintained pregnancies: abnormal nonstress tests.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16150250" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Fetal response to maternal methadone administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15001211" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : The effect of methadone treatment on the quantity and quality of human fetal movement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16443503" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Effect of chronic maternal methadone therapy on intrapartum fetal heart rate patterns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20868741" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Fetal neurobehavioral effects of exposure to methadone or buprenorphine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28188773" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Maternal buprenorphine treatment and fetal neurobehavioral development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27832443" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : The Prevalence and Impact of Substance Use Disorder and Treatment on Maternal Obstetric Experiences and Birth Outcomes Among Singleton Deliveries in Massachusetts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9519499" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : The relationship between maternal use of heroin and methadone and infant birth weight.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1445130" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Narcotic addiction in pregnancy with adverse maternal and perinatal outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2756964" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Perinatal outcome of infants exposed to cocaine and/or heroin in utero.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15635517" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Management of perioperative pain in patients chronically consuming opioids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16418412" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Acute pain management for patients receiving maintenance methadone or buprenorphine therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16534357" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Anesthetic management of the illicit-substance-using patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15220793" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Perioperative management of acute pain in the opioid-dependent patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17666599" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32293854" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Postpartum Relapse Prevention: The Family Physician's Role.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36897177" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Postpartum Opioid-Related Mortality in Patients With Public Insurance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33845029" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35438758" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Association of Duration of Methadone or Buprenorphine Use During Pregnancy With Risk of Nonfatal Drug Overdose Among Pregnant Persons With Opioid Use Disorder in the US.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32673447" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Buprenorphine Medication for Opioid Use Disorder: A Study of Factors Associated With Postpartum Treatment Retention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16923675" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Post-cesarean pain management of patients maintained on methadone or buprenorphine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15113988" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Postoperative opiate analgesia requirements of smokers and nonsmokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22396085" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Peripartum pain management in opioid dependent women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24845486" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Prenatal and postpartum care of women with substance use disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29995730" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Fatal and Nonfatal Overdose Among Pregnant and Postpartum Women in Massachusetts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31692133" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Maternal and infant characteristics associated with maternal opioid overdose in the year following delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31692133" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Maternal and infant characteristics associated with maternal opioid overdose in the year following delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25900803" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Contraceptive use and method choice among women with opioid and other substance use disorders: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25900803" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Contraceptive use and method choice among women with opioid and other substance use disorders: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4721145" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Narcotic withdrawal in pregnancy: stillbirth incidence with a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1130446" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Fetal stress from methadone withdrawal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9794682" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Opioid detoxification in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33706342" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Buprenorphine Patch as a Bridge to Sublingual Treatment of Opioid Use Disorder in Pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33378137" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Microinduction of Buprenorphine/Naloxone: A Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32011408" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Rapid Transition From Methadone to Buprenorphine Utilizing a Micro-dosing Protocol in the Outpatient Veteran Affairs Setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32011408" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Rapid Transition From Methadone to Buprenorphine Utilizing a Micro-dosing Protocol in the Outpatient Veteran Affairs Setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5352597" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Pregnancy in narcotics addicts treated by medical withdrawal. The methadone detoxification program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26996987" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Detoxification from opiate drugs during pregnancy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
